Synthesis and Bioevaluation of Iodine-131 Directly Labeled Cyclic RGD-PEGylated Gold Nanorods for Tumor-Targeted Imaging

Table 1

Biodistribution of ¹³¹IGNR-PEG-cRGD in C57BL/6 mice with B16F10 tumors and athymic mice with MCF-7 tumors at 1, 3, and 6 h after intravenous administration ().

Tissue	B16F10			B16F10 blocking	MCF-7
	1 h	3 h	6 h	6 h	1 h	3 h	6 h
Blood	3.53 ± 1.31	4.53 ± 1.58	3.19 ± 0.35	3.97 ± 1.25	3.14 ± 2.10	3.1 ± 0.31	2.44 ± 0.28
Brain	0.20 ± 0.09	0.18 ± 0.03	0.17 ± 0.02	0.15 ± 0.09	0.18 ± 0.09	0.15 ± 0.03	0.10 ± 0.02
Heart	1.14 ± 0.44	1.45 ± 0.27	0.85 ± 0.19	0.78 ± 0.17	0.45 ± 0.16	0.93 ± 0.17	0.47 ± 0.17
Lung	19.25 ± 4.59	11.74 ± 1.97	7.07 ± 0.25	6.93 ± 0.24	20.56 ± 9.24	17.41 ± 1.04	3.31 ± 1.87
Liver	32.05 ± 5.37	28.83 ± 7.17	26.51 ± 4.93	27.59 ± 5.01	30.18 ± 4.87	31.51 ± 5.71	27.60 ± 3.34
Spleen	11.28 ± 0.63	9.86 ± 1.05	5.55 ± 0.69	6.32 ± 1.01	15.99 ± 1.74	8.57 ± 0.70	6.20 ± 1.18
Kidney	2.34 ± 0.75	2.60 ± 1.04	2.29 ± 0.21	3.01 ± 0.91	2.29 ± 1.51	2.00 ± 0.36	1.50 ± 0.37
Stomach	3.59 ± 1.81	6.12 ± 2.28	3.43 ± 0.44	4.02 ± 0.59	3.49 ± 2.69	5.44 ± 2.75	4.70 ± 1.37
Intestine	1.52 ± 0.55	1.60 ± 0.57	1.23 ± 0.48	1.04 ± 0.29	1.15 ± 0.77	1.35 ± 0.25	0.89 ± 0.47
Muscle	0.47 ± 0.19	0.59 ± 0.08	0.51 ± 0.08	0.57 ± 0.12	0.54 ± 0.22	0.58 ± 0.23	0.42 ± 0.07
Bone	2.59 ± 0.78	3.29 ± 1.47	1.69 ± 0.13	1.70 ± 0.21	2.02 ± 0.85	2.72 ± 0.68	1.26 ± 0.71
Thyroid	2.88 ± 0.37	2.25 ± 1.09	2.93 ± 0.75	3.01 ± 0.92	3.26 ± 2.15	2.93 ± 0.26	3.59 ± 2.68
Tumor	3.57 ± 1.25	4.02 ± 1.45	5.09 ± 0.68	2.21 ± 0.52	1.31 ± 0.88	1.75 ± 0.26	1.59 ± 0.39
Uptake ratio
Tumor/blood	1.01 ± 0.11	0.80 ± 0.29	1.58 ± 0.13	0.56 ± 0.22	0.52 ± 0.07	0.57 ± 0.04	0.63 ± 0.19
Tumor/muscle	7.06 ± 2.53	6.89 ± 2.37	9.99 ± 2.98	3.87 ± 0.93	2.17 ± 1.06	3.26 ± 0.98	3.67 ± 0.92